Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) - an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)

Blood (2024) 144 (Supplement 1): 1766.

https://doi.org/10.1182/blood-2024-208687

Published: 2024

Journal Articles

Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL - an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Konstantinos Christofyllakis, Igor Age Kos, Bettina Altmann, Viola Poeschel, Stephanie Maurer, Vadim Lesan, Jörg-Thomas Bittenbring, Dominic Kaddu-Mulindwa, Zanir Abdi, Manfred Ahlgrimm, Sarah Altmeyer, Octavian Fleser, Gerhard Held, Maike Nickelsen, Martin Dreyling, Florian Zettl, Christian Buske, Georg Lenz, Bertram Glass, Björn Chapuy, Norbert Schmitz, German Ott, Reiner Siebert, Andreas Viardot, Florian Scherer, Roland Schmitz, Andreas Rosenwald, Dirk Hellwig, Nina Neuendorff, Theodoros Vassilakopoulos, Chrysoula Doxani, Pascal Blatt, Oguzhan Nakisli, Susanne Schmidt, Tobias Gaska, Börge Arndt, Matthias Mueller, Hanno Maximilian Witte, Martin Bentz, Volkmar Boehme, Heinz Kirchen, Markus Loeffler, Boris Kubuschock, Niklas Gebauer, Rolf Mahlberg, Julian Topaly, Alexander Bott, Kai Wille, Ralf Ulrich Trappe, Mathias J. Rummel, Gerald Illerhaus, Franziska Brunner, Martin Klump, Ulrich Kaiser, Swen Wessendorf, Iordanis Deligiannis, Bert Hildebrandt, Alexander Kiani, Thomas Illmer, Gabriele Prange-Krex, Kristina Lerch, Matthias Sandmann, Sebastian Broeckling, Uwe Martens, Bastian von Tresckow, Annkristin Heine, Holger F. Hebart, Stephan Stilgenbauer, Lorenz Thurner, Moritz Bewarder, Marita Ziepert

Blood (2024) 144 (Supplement 1): 4498.

https://doi.org/10.1182/blood-2024-199685

Published: 2024

Journal Articles

Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry

Blood (2022) 140 (Supplement 1): 818–820.

https://doi.org/10.1182/blood-2022-162252

Published: 2022

Journal Articles

Health-Related Quality of Life of CML Patients Under 2nd or 3rd Line Bosutinib Is Not Impaired Significantly By Gastrointestinal Toxicity (GI Tox) but Influenced By Sex - Results from a Subanalysis of the Bosutinib Dose Optimization (BODO) Study (CML-VII) Trial of the German CML Study Group

Susanne Isfort, Dominik Wolf, Lino L. Teichmann, Martina Crysandt, Andreas Burchert, Andreas Hochhaus, Susanne Saussele, Alexander Kiani, Joachim R Göthert, Thomas Illmer, Philippe Schafhausen, Mareille Warnken-Uhlich, Uta Wolber, Denise Kohn, Kirsi Manz, Markus Pfirrmann, Tim H.H. Brummendorf

Blood (2022) 140 (Supplement 1): 12194–12196.

https://doi.org/10.1182/blood-2022-164607

Published: 2022

Journal Articles

Step-in Dosing in the Bosutinib Dose Optimization Study (BODO) Failed to Reduce Gastrointestinal (GI) Toxicity in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) but Suggests Promising Molecular Response

Susanne Isfort, Dominik Wolf, Lino L. Teichmann, Martina Crysandt, Andreas Burchert, Andreas Hochhaus, Susanne Saussele, Alexander Kiani, Joachim R. Göthert, Thomas Illmer, Philippe Schafhausen, Mareille Warnken-Uhlich, Uta Wolber, Denise Kohn, Kirsi Manz, Markus Pfirrmann, Tim H Brümmendorf

Blood (2021) 138 (Supplement 1): 3608.

https://doi.org/10.1182/blood-2021-151240

Published: 2021

Journal Articles

Treatment-Free Remission (TFR) after Two Different Durations of Nilotinib Consolidation in Patients with Chronic Myeloid Leukemia (CML) Previously Treated with Imatinib: Enestpath Study Results

Delphine Rea, Slawomira Kyrcz-Krzemien, Paolo Sportoletti, Jiří Mayer, Arpad Illes, Anna Angona, Alexander Kiani, Aude Charbonnier, Theodoros Marinakis, Leif Stenke, Ansgar Weltermann, Seema Shah, Sharon Supekar, Luigi Di Caprio, Michele Baccarani

Blood (2021) 138 (Supplement 1): 635.

https://doi.org/10.1182/blood-2021-145611

Published: 2021

Journal Articles

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Blood (2020) 136 (7): 823–830.

https://doi.org/10.1182/blood.2019004583

Published: 2020

Includes: Supplemental data

Journal Articles

Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia

Christoph Röllig, MD MSC, Michael Kramer, M.Sc., Christoph Schliemann, Jan-Henrik Mikesch, MD, Björn Steffen, MD, Alwin Krämer, MD, Tim Sauer, MD, Mathias Hänel, MD, Regina Herbst, MD, Kerstin Schäfer-Eckart, MD, Richard Noppeney, MD, Edgar Jost, MD, Tim H Brümmendorf, MD, Stefan W Krause, MD, Volker Kunzmann, MD PhD, Hermann Einsele, MD, Sebastian Scholl, Andreas Hochhaus, MD, Lars R. Fransecky, MD, Martin Kaufmann, MD, Andreas Neubauer, MD, Dirk Niemann, MD, Markus Schaich, MD, Norbert Frickhofen, MD, Alexander Kiani, Frank Heits, MD, Ulrich Krümpelmann, Ulrich Kaiser, MD, Johannes Kullmer, Maxi Wass, MD, Stefan Klein, MD, Malte Von Bonin, Jan Moritz Middeke, MD, Christian Thiede, MD, Friedrich Stoelzel, MD, Johannes Schetelig, MDMSc, Gerhard Ehninger, MD, Claudia D Baldus, Carsten Müller-Tidow, MD, Uwe Platzbecker, Hubert Serve, MD, Martin Bornhäuser, MD

Blood (2019) 134 (Supplement_1): 13.

https://doi.org/10.1182/blood-2019-123717

Published: 2019

Journal Articles

Enestpath Leukemic Stem Cell (LSC) Sub-Study: Analyzing Characteristics of LSC-Positive Patients and Impact of Switch from Imatinib to Nilotinib Therapy on LSCs in Patients with Chronic Myeloid Leukemia

Fermin Sanchez-Guijo, MD PhD, Sergio Matarraz, Eleni Plata, Miguel Sagüés, Montserrat Cortes, Irena Preloznik Zupan, Monica Crugnola, MD, Giovanni Caocci, MD, Heather Oakervee, BSc, MBBS, MD MRCP, FRCPath, Tobias Gedde-Dahl, Krzysztof Warzocha, Wieslaw W. Jedrzejczak, Slawomira Kyrcz-Krzemien, MD PhD, Alexander Kiani, Sharon Supekar, AnaRita Ferreira, Seema Shah, Juan Luis Steegmann, Michele Baccarani, MD

Blood (2019) 134 (Supplement_1): 4160.

https://doi.org/10.1182/blood-2019-124710

Published: 2019

Journal Articles

The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial

Christoph Rollig, MD MSC, Hubert Serve, Andreas Hüttmann, MD, Richard Noppeney, MD, Carsten Müller-Tidow, Utz Krug, Claudia D. Baldus, MD, Christian H. Brandts, MD, Volker Kunzmann, MD PhD, Hermann Einsele, Alwin Krämer, MD, Kerstin Schäfer-Eckart, MD, Andreas Neubauer, MD, Andreas Burchert, MD, Aristoteles Giagounidis, MD, Stefan W. Krause, Andreas Mackensen, MD, Walter E. Aulitzky, MD, Regina Herbst, MD, Mathias Hänel, MD, Alexander Kiani, Norbert Frickhofen, MD, Johannes Kullmer, Ulrich Kaiser, MD, Hartmut Link, MD PhD, Thomas Geer, MD, Albrecht Reichle, MD, Christian Junghanss, MD, Roland Repp, MD, Frank Heits, MD, Heinz Albert Durk, Thomas Illmer, Martin Bornhäuser, MD, Markus Schaich, MD, Stefani Barbara Parmentier, MD, Martin Goerner, MD, Christian Thiede, MD, Malte von Bonin, MD, Johannes Schetelig, MD, Michael Kramer, M.Sc., Wolfgang E. Berdel, Gerhard Ehninger

Blood (2017) 130 (Supplement 1): 721.

https://doi.org/10.1182/blood.V130.Suppl_1.721.721

Published: 2017

Journal Articles

Improved Safety with the Use of Subcutaneous Bortezomib in Combination with Panobinostat and Dexamethasone: Preliminary Data from a Panobinostat Global Expanded Treatment Protocol

Blood (2016) 128 (22): 5692.

https://doi.org/10.1182/blood.V128.22.5692.5692

Published: 2016

Journal Articles

Azacitidine Followed By Intensive Induction/Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML): Results from the Randomized AML-AZA Trial of the Study Alliance Leukemias (SAL)

Carsten Müller-Tidow, MD, Petra Tschanter, MD, Utz Krug, MD, Stefanie Goellner, PhD, Christoph Röllig, MD, Christian Thiede, MD, Anja Koschmieder, Martin Dugas, PhD, Joachim Gerss, PhD, Trude Butterfaß-Bahloul, Ruth Wagner, Stefan W. Krause, MD, Ulrich Kaiser, Volker Kunzmann, MD, Björn Steffen, MD, Richard Noppeney, MD, Wolfgang Herr, MD, Claudia D Baldus, Norbert Schmitz, MD, Katharina Götze, Albrecht Reichle, Martin Kaufmann, MD, Andreas Neubauer, MD, Kerstin Schäfer-Eckart, MD, Mathias Hänel, MD, Rudolf Peceny, MD, Haack Bea, Lilly Meredith, Norbert Frickhofen, MD, Michael G Kiehl, MD, Aristoteles A.N. Giagounidis, MD PhD, Martin Görner, Roland Repp, MD, Ralph Naumann, MD, Hartmut Link, MDPhD, Alexander Kiani, MD, Steffen Koschmieder, MD, Tim H. Brümmendorf, MD, Hubert Serve, MD, Gerhard Ehninger, MD, Wolfgang E Berdel, MD

Blood (2014) 124 (21): 946.

https://doi.org/10.1182/blood.V124.21.946.946

Published: 2014

Journal Articles

Lack of the Transcription Factor NFAT (Nuclear Factor of Activated T cells) c2 in Hematopoietic Progenitor Cells Results in Profound Hematological Abnormalities in Mice

Laleh S. Arabanian, Michael Haase, MD, Ivonne Habermann, Malte von Bonin, MD, Claudia Waskow, PhD, Rainer Ordemann, MD, Gerhard Ehninger, MD, Alexander Kiani, MD

Blood (2011) 118 (21): 1296.

https://doi.org/10.1182/blood.V118.21.1296.1296

Published: 2011

Journal Articles

Prophylactic transfer of BCR-ABL–, PR1-, and WT1-reactive donor T cells after T cell–depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia

Martin Bornhäuser, Christian Thiede, Uwe Platzbecker, Alexander Kiani, Uta Oelschlaegel, Jana Babatz, Doris Lehmann, Kristina Hölig, Jörgen Radke, Sebastian Tuve, Martin Wermke, Rebekka Wehner, Hanka Jähnisch, Michael P. Bachmann, E. Peter Rieber, Johannes Schetelig, Gerhard Ehninger, Marc Schmitz

Blood (2011) 117 (26): 7174–7184.

https://doi.org/10.1182/blood-2010-09-308569

Published: 2011

Journal Articles

Minimal Residual Disease (MRD) Based Preemptive 5–Azacytidine Treatment Can Prevent or Delay Imminent Relapse In Patients with High-Risk MDS or AML After Allogenic HSCT – Results of the “RELAZA” Trial

Uwe Platzbecker, Martin Wermke, Jörgen Radke, Alexander Kiani, Franzi Seltmann, Christoph Röllig, Malte von Bonin, Brigitte Mohr, Uta Oelschlägel, Johannes Schetelig, Gerhard Ehninger, Martin Bornhäuser, Christian Thiede

Blood (2010) 116 (21): 679.

https://doi.org/10.1182/blood.V116.21.679.679

Published: 2010

Journal Articles

Prior Treatment with Alemtuzumab Interferes with T-Cell Engraftment After Allogeneic Stem Cell Transplantation in Patients with Chronic Lymphocytic Leukemia.

Johannes Schetelig, Christian Thiede, Alexander Kiani, Uwe Platzbecker, Uta Oelschlaegel, Matthias Haenel, Gaby Geissler, Rainer Schwerdtfeger, MD, Karin Kolbe, MD, Martin Kaufmann, Matthias Zeis, MD, Kerstin Schaefer-Eckart, MD, Wolfgang Siegert, MD, PhD, Gerhard Ehninger

Blood (2009) 114 (22): 3351.

https://doi.org/10.1182/blood.V114.22.3351.3351

Published: 2009

Journal Articles

Regulation of Fas/Fas Ligand-Mediated Apoptosis in Megakaryocytes by Nuclear Factor of Activated T Cells.

Laleh S. Arabanian, Satu Kyttälä, Ph.D., Ivonne Habermann, Gerhard Ehninger, M.D., Alexander Kiani, MD

Blood (2009) 114 (22): 4023.

https://doi.org/10.1182/blood.V114.22.4023.4023

Published: 2009

Journal Articles

Flow Cytometric Detection of Minimal Residual Disease One Year Post Allogeneic Stem Cell Transplantation Predicts Outcome in Patients with B-CLL.

Uta Oelschlaegel, Martin Bornhäuser, Alexander Kiani, Uwe Platzbecker, Christoph Röllig, Martin Wermke, Christian Thiede, Gerhard Ehninger, Johannes Schetelig

Blood (2009) 114 (22): 202.

https://doi.org/10.1182/blood.V114.22.202.202

Published: 2009

Journal Articles

Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial).

Blood (2009) 114 (22): 131.

https://doi.org/10.1182/blood.V114.22.131.131

Published: 2009

Journal Articles

Graft Versus Host Disease (GVHD) Prophylaxis with Everolimus and Tacrolimus Is Associated with a High Incidence of Sinusoidal Obstruction Syndrome and Microangiopathy – Results of the EVTAC Trial

Uwe Platzbecker, Malte Bonin, Eray Goekkurt, Joergen Radke, Alexander Kiani, Jan Stoehlmacher, Johannes Schetelig, Gerhard Ehninger, Martin Bornhauser, MD

Blood (2008) 112 (11): 1172.

https://doi.org/10.1182/blood.V112.11.1172.1172

Published: 2008

NARROW

Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) - an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)

Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL - an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry

Health-Related Quality of Life of CML Patients Under 2nd or 3rd Line Bosutinib Is Not Impaired Significantly By Gastrointestinal Toxicity (GI Tox) but Influenced By Sex - Results from a Subanalysis of the Bosutinib Dose Optimization (BODO) Study (CML-VII) Trial of the German CML Study Group

Step-in Dosing in the Bosutinib Dose Optimization Study (BODO) Failed to Reduce Gastrointestinal (GI) Toxicity in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) but Suggests Promising Molecular Response

Treatment-Free Remission (TFR) after Two Different Durations of Nilotinib Consolidation in Patients with Chronic Myeloid Leukemia (CML) Previously Treated with Imatinib: Enestpath Study Results

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia

Enestpath Leukemic Stem Cell (LSC) Sub-Study: Analyzing Characteristics of LSC-Positive Patients and Impact of Switch from Imatinib to Nilotinib Therapy on LSCs in Patients with Chronic Myeloid Leukemia

The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial

Improved Safety with the Use of Subcutaneous Bortezomib in Combination with Panobinostat and Dexamethasone: Preliminary Data from a Panobinostat Global Expanded Treatment Protocol

Azacitidine Followed By Intensive Induction/Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML): Results from the Randomized AML-AZA Trial of the Study Alliance Leukemias (SAL)

Lack of the Transcription Factor NFAT (Nuclear Factor of Activated T cells) c2 in Hematopoietic Progenitor Cells Results in Profound Hematological Abnormalities in Mice

Prophylactic transfer of BCR-ABL–, PR1-, and WT1-reactive donor T cells after T cell–depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia

Minimal Residual Disease (MRD) Based Preemptive 5–Azacytidine Treatment Can Prevent or Delay Imminent Relapse In Patients with High-Risk MDS or AML After Allogenic HSCT – Results of the “RELAZA” Trial

Prior Treatment with Alemtuzumab Interferes with T-Cell Engraftment After Allogeneic Stem Cell Transplantation in Patients with Chronic Lymphocytic Leukemia.

Regulation of Fas/Fas Ligand-Mediated Apoptosis in Megakaryocytes by Nuclear Factor of Activated T Cells.

Flow Cytometric Detection of Minimal Residual Disease One Year Post Allogeneic Stem Cell Transplantation Predicts Outcome in Patients with B-CLL.

Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial).

Graft Versus Host Disease (GVHD) Prophylaxis with Everolimus and Tacrolimus Is Associated with a High Incidence of Sinusoidal Obstruction Syndrome and Microangiopathy – Results of the EVTAC Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only